Aeovian Pharmaceuticals
PrivateLast Round
Series B
Dec 16, 2025
Total Funding Raised
$142M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Aeovian Pharmaceuticals is a biotechnology company that develops targeted and highly selective small molecule therapeutics to restore cellular metabolic quality control for the treatment of rare and age-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aeovian Pharmaceuticals Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Aeovian Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 16, 2025 | ||||
| Series A Extension | Mar 28, 2024 | ||||
| Series A | Oct 3, 2019 | ||||
| Seed | Dec 11, 2017 |
Key People
Founding team and executive leadership
Aeovian Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apollo Ventures | Seed |
| SymBiosis Capital Management | Series B |
| CTI Life Sciences Fund | Series B |
| TSC Alliance Endowment Fund | Series B |
| Hevolution Foundation | Series B, Series A Extension |
| LUMA Partners | Series B |
| Foresite Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 16, 2025
$55M Series B round completed.
- Dec 16, 2025
Youssef Bennani joins the Board of Directors.
Aeovian Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aeovian Pharmaceuticals's valuation, stock price, and market status.